HALO: Halozyme Inc. P/S Multiple

Brandmark of Halozyme Corp (HALO)

The price/sales multiple for Halozyme Therapeutics (HALO) reflects the valuation dynamics of Halozyme Therapeutics (HALO), where 6.30 represents the current metric. The business model relies on outsourcing enzyme production to third-party contractors. Revenues are diversified through the sale of drug delivery rights to global players. The high margins of the ENHANZE platform ensure a steady capital inflow, confirming the relevance of its technological solutions.

Halozyme Inc. - HALO Price-to-Revenue Ratio (period 07/04/2022 - 11/16/2026)

Halozyme Therapeutics, Inc. (HALO) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Fundamental company analysis:HALO (Halozyme)
Flagship merchandise of Halozyme

The P/S multiple compares market capitalization to annual sales volume, allowing for an assessment of the premium paid per unit of revenue regardless of profit. By analyzing the ratio of company value to annual revenue, an investor determines whether the growth premium is justified, which is critical for Halozyme Therapeutics (HALO) when scaling licensing royalties and monetizing enzyme technologies with minimal operating expenses.

Competing companies

ONC - Price to Sales|P/S Multiple RVMD (revmed.com)|Price-to-Revenue Coefficient Ascentage (AAPG)|CGON: Market Cap to Revenue|Price to Sales UroGen Pharma Ltd.|BCAX: P/S Multiple|PSNL - Price-to-Revenue Coefficient|ERAS (Erasca Oncology) - P/S Multiple|P/S Multiple Delcath Systems, Inc.|Price-to-Revenue Ratio ymabs.com (YMAB)|Price-to-Revenue Ratio AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Market Cap to Revenue|Accuray Inc. (ARAY) - Price to Sales|SELLAS Life Sciences Group, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd